15 10, 2024

Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus

2024-10-15T07:46:12+02:00October 15th, 2024|biomarker, bone diseases, bone fracture risk assessment, diabetes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus

Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of miRNAs such as mmu-miR-466i-5p and mmu-miR-1195 in both serum and bone marrow of diabetic mice. Dysregulated miRNAs were linked to pathways associated with diabetes-related signaling and diabetic bone disease, shedding light on potential mechanistic pathways. Cell-type enrichment analysis pointed towards miRNAs enriched in specific cell types like immune cells, hepatocytes, and mesenchymal stem cells, [...]

18 09, 2024

Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers

2024-09-18T14:10:09+02:00September 18th, 2024|biomarker, biomarkers, exosomes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers

A new study from the University of Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. This research, leveraging TAmiRNA's Next-Generation Sequencing (NGS)-based miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific EVs and their miRNA cargo. Interested in our of extracellular vesicles (EVs) and exosomes services - click here! click here to read the paper

9 08, 2024

Eager to lern more about Early Detection of Colorectal Cancer through MicroRNA Profiling

2024-08-09T11:17:20+02:00August 9th, 2024|biomarker, biomarkers, exosomes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Eager to lern more about Early Detection of Colorectal Cancer through MicroRNA Profiling

TAmiRNA and its partner Biomedica are proud to announce that researchers from the Jagiellonian University Medical College used our innovative small RNA-sequencing pipeline (miND®) to unravel novel miRNA expression profiles in colorectal cancer cell lines and the extracellular vesicles (EVs) they produce. Colorectal cancer ranks as the third most common cancer in men and the second in women globally. Late diagnosis significantly contributes to rising morbidity and mortality rates, emphasizing the urgent need for new markers for early and precise detection. The analysis of miRNAs in plasma-derived EVs and tumor samples from CRC patients revealed a similar miRNA expression profile between patient samples and CRC cell lines. Importantly, miR-182-5p, miR-196b-5p, miR-425-5p, and miR-429 were found regulated in [...]

3 06, 2024

LEPTON and TAmiRNA collaborate on microRNA immune therapy discovery

2024-06-03T10:16:12+02:00June 3rd, 2024|biomarker, biomarkers, microRNA services, microRNAs, sequencing, smallRNA|Comments Off on LEPTON and TAmiRNA collaborate on microRNA immune therapy discovery

Lepton Pharmaceuticals LTD (Lepton), a biopharmaceutical company, focused on discovery and development of novel treatments for unmet medical needs, exploiting the subtle silencing of coding RNA expression by noncoding RNA molecules microRNA (miRNA) and small interfering RNA, and TAmiRNA GmbH, a research and development company specialized in the discovery and validation of microRNA biomarkers to improve patients’ life, announce the reinforcement of their collaboration by signing a second agreement to discover the epigenetic pathways that affect the activity of microRNAs thereby improving genetically modified immune cells therapy. Lepton together with Freiburg University is developing a technology (the Castling Technology) for enhancement of immune cells (T-cells or CAR T-cells, B-cells, natural killer (NK) cells, T-regulatory cells, macrophages, stem cells [...]

24 04, 2024

EVscale™ platform

2024-06-14T08:13:58+02:00April 24th, 2024|biomarker, Evercyte, exosomes, extracellular vesicle, microRNA services, microRNAs, miND spike ins, NGS, Phoenestra, sequencing, smallRNA|Comments Off on EVscale™ platform

The EVscale™ platform, developed by Evercyte, Phoenestra, and TAmiRNA, offers a comprehensive solution for pharmaceutical and biotech manufacturers requiring exosomes and EVs at commercial scale. Drawing on the combined expertise of the three partners, EVscale™ provides customizable projects, including specific cell sourcing, EV characterization, scalable manufacturing, and linking EV biological functions to RNA and protein EV components. EVscale™ advantages: Offers a fundamental advantage over conventional sourcing of therapeutic exosomes from primary cells, eliminating donor-to-donor variability and other issues like scaling difficulties, variable process performance, inconsistent batch quality, and under-developed downstream processing technologies. Provides a unique one-stop-shop offer, allowing customers to tailor end-product parameters based on their project’s specific needs. By combining miRNomics with transcriptomic and proteomic analyses, [...]

10 04, 2024

Eager to lern more about Sepsis-associated acute kidney injury?

2024-04-10T13:16:00+02:00April 10th, 2024|biomarker, biomarkers, microRNA services, microRNAs, microstructure, miND spike ins, NGS, sequencing, smallRNA, Vivomicx|Comments Off on Eager to lern more about Sepsis-associated acute kidney injury?

We are pleased to share our latest publication, a collaborative effort with TAmiRNA, titled 'Sepsis-Induced Heterogeneous Transcription of Coagulation- and Inflammation-Associated Genes in Renal Microvasculature,' which has been published in Thrombosis Research. Through the integration of TAmiRNA's high-sensitivity gene expression profiling techniques (RT-qPCR and smallRNAseq/RNAseq) and the advanced laser microdissection technology from Dutch company Vivomicx, our study unveils the diverse transcriptional responses of microvascular compartments to sepsis-associated acute kidney injury (SA-AKI). Our findings demonstrate that distinct changes occur in the expression of coagulation- and inflammation-related genes across microvascular compartments in response to SA-AKI. This heterogeneity underscores the complexity of the microvascular response to sepsis and highlights potential avenues for targeted therapeutic intervention. Moving forward, our research will [...]

4 04, 2024

Exciting news!

2024-04-04T13:16:30+02:00April 4th, 2024|biomarker, biomarkers, Illumina NewSeq2000, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Exciting news!

We just received the Illumina NextSeq 2000 machine, marking a significant milestone in our journey towards cutting-edge research and innovation. This powerful instrument will drive our NGS services and allow us to deliver results quicker than ever before.

13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

Go to Top